Treatment of rheumatoid arthritis: A review of recommendations and emerging therapy
Rheumatoid arthritis (RA) is a complex disease, resulting in localized erosion to the joint and its accessory structures. Due to the progressive nature of the disease, extra-articular complications will occur in multiple organ systems. Over the past decade, the management of RA has evolved with disease-modifying antirheumatic agents with biologic activity targeting specific components of the immune system. With advanced therapy, management includes halting further progression of the disease and maintaining quality of life. The American College of Rheumatology has provided updated guidelines regarding the use of biologic therapies as monotherapy or in combination with nonbiologic therapy such as methotrexate. Unmet needs remain, however, for the management of RA due to the complexity of the disease. Innovative agents are needed to create additional strategies and achieve desired goals for its management. (Formulary. 2011;46:532–545.)
Rheumatoid arthritis (RA) is characterized as a chronic, inflammatory disease in which the immune system destroys synovial joints and accessory structures.1,2 Due to the progressive nature, this autoimmune condition can cause extra-articular complications within several organ systems.3 RA is the most common autoimmune disease, and the second most common form of arthritis compared to osteoarthritis (OA).1,2
RA affects approximately 1% of adults all over the world.1,2 Individuals are usually diagnosed between the third and fifth decade of life and women are 2 to 3 times more likely to be diagnosed than men.1,2 Therefore, individuals with RA may experience a lower quality of life and amass a large amount of direct and indirect costs due to the management of the disease, hospitalizations, and physician visits.
The etiology of RA is not fully understood, but environmental and genetic factors have been proposed as potential theories. Genetic predisposition results in the destructive nature of this autoimmune disease.2 The inheritance of certain genes in the major histocompatibility complex can increase the susceptibility of developing RA. For example, an individual with expression of a human leukocyte antigen (HLA) DR-4 antigen will be 3.5 times more likely to develop RA compared to someone with other HLA-DR antigens.2 Other potential risk factors include female gender, use of oral contraceptives, tobacco use, and infectious agents.2
Synovial joints, such as the knee, have the most flexibility due to unity of bones by connective tissue of an articular capsule and accessory ligaments. In RA, the immune response will be activated in an early stage of life. This immune response could be triggered by genetic and environmental factors. Once the immune system is unbalanced, subclinical inflammation will occur due to activation of T cells from an antigen-presenting cell. Once T cells are proliferated, a cascade of events occurs in the immune system: activation of B cells and macrophages, as well as other proinflammatory mediators such as tumor necrosis factor (TNF) and interleukin (IL). As the immune system remains unchecked, symptoms associated with RA will occur and the criteria for the disease will be fulfilled. Once the diagnosis is confirmed, the pathologic inflammatory response can continue, resulting in joint destruction and extra-articular complications. Within a synovial joint, bone and cartilage erosion will occur, causing a swollen joint capsule and inflamed joint synovium. The extra-articular complications can occur over time and include infections, lymphomas, cardiovascular disease, and osteoporosis.1-3
ACR and EULAR have specific treatment guidelines for RA.6-8 Once a diagnosis is made, the combination of nonpharmacologic and pharmacologic therapy should be initiated. Initially, education is always warranted regarding the disease and its progressive nature. Depending on the patient's level of disability, physical and/or occupational therapy should be considered to improve quality of life. Overall, pharmacologic therapy is the mainstay of treatment for RA and can be divided into symptomatic therapy and disease-modifying antirheumatic drugs (DMARDs). Even though the treatment has emerged with innovative, more-specific agents, there is no cure for RA. Aggressive treatment is used to prevent further progression of the disease and help maintain the patient's quality of life.
TREATMENT OF RA
In 2008, ACR developed new recommendations from the 2002 guidelines on the treatment of RA.6,7 In addition, EULAR published updated guidelines in 2010, which are similar to the updates by ACR.8 The purpose of the new recommendations was to provide additional guidance from clinical evidence and input of an expert panel. Overall, the guidelines are similar in their recommendations. Treatment with a DMARD should begin as soon as the diagnosis of RA is confirmed. Therapy can be intensified every 3 to 6 months with nonbiologic and/or biologic DMARDs, with methotrexate as part of the treatment regimen unless contraindicated or not tolerated.
Due to the progressive nature of the disease, there can be extra-articular complications for patients with RA. One of the major complications can be cardiovascular mortality or morbidity.9,10 In 2010, EULAR published 10 key recommendations regarding cardiovascular risk screening and management for patients with RA, as well as other inflammatory conditions (ie, ankylosing spondylitis and psoriatic arthritis).9 In general, the recommendations recognize early identification of cardiovascular risk factors due to the increased prevalence in the general population and inflammatory properties of the disease. Adequate risk management and ongoing monitoring is recommended to lower the cardiovascular risk of a patient with RA. For example, it is recommended that all patients with RA should undergo an annual cardiovascular risk assessment using a risk-score model. EULAR recommends the use of national guidelines for determining the appropriate management of a patient's hypertension or yperlipidemia, such as statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers. For the treatment of RA, cyclooxygenase (COX-2) inhibitors and nonsteroidal anti-inflammatory drugs (NSAIDs) should be prescribed cautiously for a patient with or without documented cardiovascular disease, weighing the risks and benefits. The lowest possible dose of an oral corticosteroid should be prescribed due to the long-term safety profile (ie, hypertension, yperlipidemia, atherosclerosis). Lastly, smoking cessation should be encouraged among all patients with RA who actively smoke.9
NSAIDs. NSAIDs have been used in the management of RA for several decades. NSAIDs inhibit COX to prevent further formation of prostaglandins and other related inflammatory mediators. Based on its mechanism of action, NSAIDs are useful adjuvant therapy for the symptomatic management of RA, as this class of medications can reduce joint swelling, tenderness, and pain.6,11,12 All NSAIDs pose anti-inflammatory properties and, when prescribed at high doses, are equally effective. As a class, the main disadvantage of NSAIDs includes the safety profile (ie, gastrointestinal [GI], nephrotoxicity, and cardiovascular). In addition, it is difficult to predict an individual's response with a particular NSAID. Compared to more-specific agents (ie, COX-2 inhibitor), there is no superior evidence between these therapeutic classifications of medications.6,11 Therefore, celecoxib is the only COX-2 inhibitor that can be an alternative agent for an individual prone to GI bleeding or ulcers.
Corticosteroids. Corticosteroids possess anti-inflammatory and immunosuppressive properties through an unknown specific mechanism. However, it is suspected that these agents have inhibitory properties on the generation and migration of immune system mediators. Similar to NSAIDs, corticosteroids are commonly used for symptomatic management.6,11 The advantage of corticosteroids is the available oral and intra-articular formulations for the treatment of RA. Therefore, a patient can receive systemic or localized corticosteroid treatment based on clinical presentation, particularly with joint involvement. Intra-articular injections are useful when 1 large joint is involved in the clinical presentation. Specific instructions, however, should be provided to the patient regarding intra-articular injections. Corticosteroids may be used as bridge therapy with DMARDs to avoid long-term adverse events. Some patients also will require continuous therapy to maintain remission of the disease. With continuous therapy, ACR recommends the lowest dose of corticosteroid (eg, prednisone <10 mg daily/d) to control symptoms and reduce the risk of adverse events.6 High doses of corticosteroids also may need to be prescribed as "burst" therapy during exacerbations.
Several therapies for RA are currently being investigated to achieve the unmet needs of its management, such as oral and less expensive medications; the most promising therapies include tofacitinib, fostamatinib, veltuzumab, ofatumumab, apremilast, and secukinumab.13–33
Tofacitinib is an oral Janus kinase (JAK) inhibitor, which will block the signaling for cytokine proliferation.13 This investigational agent is not a specific inhibitor for a proinflammatory immune system mediator. Tofacitinib, however, targets multiple cytokines to prevent inflammation and further erosion and damage to joints and accessory structures.13 In clinical trials, this JAK inhibitor has been effective to reduce ACR clinical parameters, but each trial has differed in the study design, dosage of tofacitinib, and patient population.14–16 The safety concern with tofacitinib includes long-term immunosuppression due to its mechanism of action on the immune system and chronic dosing characteristics. In addition, cardiac events may be a concern due to the dose-dependent changes in the cholesterol panel.13 It is predicted that the manufacturer will be submitting a new drug application of tofacitinib for FDA approval at the end of the year. If approved, tofacitinib may be a competitor for other DMARDs with biologic activity, but long-term safety will continue to be a concern among practitioners.
Fostamatinib is a tyrosine kinase inhibitor, which blocks signaling to immune cells. This cell signal inhibition will prevent the proliferation of immune cell mediators to cause further destruction on the joint synovium.17 In a phase 2 multicenter, randomized, double-blind trial, fostamatinib was studied for 6 months among patients who failed methotrexate or other biologic therapies. No significant difference was found in efficacy end points between the doses of fostamatinib (100 mg daily orally twice daily vs 150 mg daily orally once daily), but each dose was superior to placebo. This trial may generate interest to investigate fostamatinib among a subpopulation of patients with an elevated C-reactive protein due to an improvement in clinical outcomes from baseline. The most common adverse events in this trial were nausea and diarrhea at both doses of fostamatinib.18 Phase 3 trials are needed to investigate the use of fostamatinib among certain subpopulations to determine its role as a potential alternate DMARD.
Veltuzumab and ofatumumab are similar agents to rituximab; these agents are monoclonal antibodies, blocking the CD20 signal to prevent the proliferation of immature and mature B lymphocytes. For veltuzumab, a phase 2 trial has currently been suspended to clarify issues about drug production and filling process; it will be several years before any clinical results are available.19 Ofatumumab is currently approved for chronic lymphocytic leukemia;20 due to its mechanism of action, it will be an alternative agent among patients with RA who have had an inadequate response to methotrexate or other biologic therapies, particularly TNF antagonists.21–23 The disadvantage for ofatumumab would be infusion delivery, which may not be convenient for patients.20 Ocrelizumab is another agent with inhibitory properties of CD20 signal for B-lymphocyte proliferation; however, clinical trials for RA were suspended because ocrelizumab increased the risk of opportunistic infections.24
Apremilast is a type 4 phosphodiesterase (PDE-4) inhibitor, which is involved with the inhibition of TNF production. This particular type of PDE is expressed on macrophages, lymphocytes, and neutrophils.25 Currently, phase 2 clinical trials are under way to determine the role of this agent in RA.26–28
Secukinumab is a humanized monoclonal antibody, targeting IL-17A; this specific target inhibits the migration of monocytes and neutrophils around the site of inflammation.29 This particular agent has been investigated as 150 mg daily subcutaneous psoriasis treatment.29 Based on its mechanism of action, secukinumab may be an option for RA due to a potential role on autoimmune diseases.30–33
Over recent months, several updates have been reported. In the June issue of the Journal of the American Medical Association, a retrospective cohort study was published regarding the risk of diabetes mellitus with DMARDs among patients with RA.34 The purpose of the study was to evaluate newly diagnosed diabetes among patients with RA or psoriasis on a particular drug regimen. These drug regimens included a TNF antagonist with or without another DMARD, methotrexate without a TNF antagonist or hydroxychloroquine, hydroxychloroquine without a TNF antagonist or methotrexate, or other DMARDs without biologic activity. After an evaluation of 13,905 subjects, an increased incidence rate of new onset of diabetes was found among the various drug regimens: 50.2 for DMARDs without biologic activity, 19.7 for TNF antagonists, 23.8 for methotrexate, and 22.2 hydroxychloroquine per 1,000 person-years. When compared to DMARDs with nonbiologic activity, TNF antagonists and hydroxychloroquine had a lower adjusted risk for diabetes (hazard ratio [HR], 0.62 and 0.54, respectively), whereas methotrexate had an HR of 0.77. This study has several weaknesses, including the lack of randomization with the study design.34 In addition, it is difficult to determine or assess the classification diabetes among participants because the American Diabetes Association (ADA) has changed the diagnostic criteria of diabetes in recent years. In the study, the 2010 ADA guidelines or physician-established criteria defined a diagnosis of diabetes. Finally, no differentiation was made between diabetes classifications (type 1 or type 2). A randomized controlled trial would need to be considered to determine the prevention of diabetes among DMARDs.
In July 2011, golimumab did not receive an expansion on its product label.35 FDA denied the expansion of the label to inhibition of progressive structural damage, induction of clinical response, and maintenance of clinical presentation, as well as physical function among patients with RA. The denial of its label expansion was due to the lack of clinical trials to support the drug's claims, as well as potential risks regarding golimumab's safety from postmarketing data. Hypersensitivity and anaphylactic reactions have been reported through adverse events reporting to the FDA.35
In August 2011, FDA approved a subcutaneous formulation of abatacept.36 In addition to an infusion, it will be available as a self-injectable subcutaneous formulation at a fixed dose of 125 mg daily weekly. For patients failing abatacept infusion, an intravenous loading dose will not be required prior to the initiation of weekly injections with abatacept. Patients who have never received abatacept, however, will be required to receive an intravenous loading dose of 10 mg daily/kg prior to initiation of weekly injections.36 Abatacept is now the only DMARD with biologic activity available in both subcutaneous and intravenous formulations.
For TNF antagonists, a couple of recent updates may impact prescribing by practitioners. First, a recent study published in Rheumatology concluded that there is a higher risk of nonmelanoma skin cancer among patients receiving TNF antagonists.37 The incidence of this particular cancer was 18.9 per 100 patient-years; when compared to a DMARD without biologic activity, the HR was 1.42 for TNF antagonists in the risk of nonmelanoma skin cancer. The greatest risk was among patients of advanced age, male gender, use of NSAIDs or corticosteroids, and prior history of malignancies.37 Although this study demonstrated a causal relationship between TNF antagonists and nonmelanoma skin cancer, it is difficult to make direct conclusions due to the observational study design. However, it may lead to additional patient education in regard to a complete skin examination for patients with RA who are receiving TNF antagonists. TNF antagonists also will get an updated black box warning regarding the risk of bacterial infections.38 Due to postmarketing data, Listeria and Legionella infections will be included in the warning given the consistent information of these infections from adverse event reporting.38 This particular update further emphasizes the importance of patient education prior to the initiation of TNF antagonists, in which all patients should be informed and evaluated for active infections (including bacterial), herpes zoster infection, hepatitis B and C, and active or latent tuberculosis.
In regard to symptomatic therapy, a recent article in Circulation focused on the determination of the duration of NSAID treatment and relationship with cardiovascular risk among patients with previous myocardial infarction (MI).39 Using nationwide registries, the length of time of first MI and NSAID use was determined by incidence rates. Among approximately 84,000 patients, there was an HR of 1.45 associated with NSAID use and the risk of death and/or recurrent MI. Among the NSAID class, diclofenac was associated with the highest risk (HR, 3.26). Among patients with a history of recurrent or prior MI, NSAIDs should be avoided as both short-and long-term use.39
For the management of RA, the goal is to slow disease progression and prevent disability, such as loss of physical function. If approved, the emerging therapies for RA may not change the algorithm for RA and approval by FDA may be several years from the present time. Treatment guidelines, however, have been updated to support the use of early, aggressive treatment for a patient with RA. On the downside, economic considerations may be a drawback to existing, advanced therapies and emerging therapies. Additional evidence will be needed given that clinical trials with RA have exhibited wide variability in the patient population, clinical outcomes, and interventions. Long-term benefits remain to be seen, and more comparative studies with standard of care are needed.
Dr Clements is assistant professor of pharmacy practice, Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, Va.
Disclosure Information: The author reports no financial disclosures as related to products discussed in this article.
1. O'Dell JR. Rheumatoid arthritis. In: Goldman L, Schafer AI, eds. Goldman's Cecil Medicine, 24th ed. Philadelphia, PA: Saunders Elsevier; 2011:1681–1689.
2. Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Firestein GS, Budd RC, Harris ED Jr, et al, eds. Kelley's Textbook of Rheumatology, 8th ed. Philadelphia, PA: Saunders Elsevier; 2008:1035–1086.
3. Harris ED Jr, Firestein GS. Clinical features of rheumatoid arthritis. In: Firestein GS, Budd RC, Harris ED Jr, et al, eds. Kelley's Textbook of Rheumatology, 8th ed. Philadelphia, PA: Saunders Elsevier; 2008:1087–1118.
4. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–324.
5. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology and European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;69(9):2569–2581.
6. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Arthritis Rheum. 2002;46(2):328–346.
7. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762–784.
8. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964–975.
9. Peters MJL, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–331.
10. Kaplan MJ. Cardiovascular complications of rheumatoid arthritis - Assessment, prevention and treatment. Rheum Dis Clin North Am. 2010;36(2):405–426.
11. Birch JT Jr, Bhattacharya S. Emerging trends in diagnosis and treatment of rheumatoid arthritis. Prim Care. 2010;37(4):779–792.
12. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–1108.
13. Yamaoka K, Kubo S, Sonomoto K, et al. JAK inhibitor: Tofacitinib, a new disease modifying anti-rheumatic drug. Inflammation Regeneration. 2011;31(4):349–353.
14. Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: Results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2010;69(2):413–416.
15. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: Scientific rationale and clinical outcomes. Best Pract Res Clin Rheum. 2010;24:513-526.
16. Bonilla-Hernán MG, Miranda-Carús ME, Martin-Mola E. New drugs beyond biologics in rheumatoid arthritis: The kinase inhibitors. Rheumatology. 2011;50(9):1542–1550.
17. Okamoto H, Kobayashi A. Tyrosine kinases in rheumatoid arthritis. J Inflammation. 2011;8:21.
18. Weinblatt ME, Kavanaugh A, Genovese MC, et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010;363:1303–1312.
19. VELVET, a dose range finding trial of veltuzumab in subjects with moderate to severe rheumatoid arthritis. http://clinicaltrials.gov/ identifier: NCT 01390545. Accessed December 1, 2011.
20. Arzerra (ofatumumab) [prescribing information]. Research Triangle Park, NC: Glaxo-SmithKline; revised, September 2011.
21. Investigating clinical efficacy of ofatumumab in adult rheumatoid arthritis (RA) patients who had an inadequate response to MTX therapy. Available at: http://clinicaltrials.gov/ identifier: NCT 00611455. Accessed December 1, 2011.
22. Investigating clinical efficacy of ofatumumab in adult rheumatoid arthritis (RA) patients who had an inadequate response to TNF-α antagonist therapy. Available at: http://clinicaltrials.gov/ identifier: NCT 00603525. Accessed December 1, 2011.
23. Long-term efficacy and safety of repeated ofatumumab treatment courses in RA patients who previously received ofatumumab or placebo in trial Hx-CD20-403. Available at: http://clinicaltrials.gov/ identifier: NCT 00655824. Accessed December 1, 2011.
24. Roche news brief. Media release. March 8, 2010. Roche and Biogen Idec decide to suspend ocrelizumab treatment – rheumatoid arthritis development programme on hold. Available at: http://www.roche.com/media/media_releases/med-cor-2010-03-08.htm. Accessed December 1, 2011.
25. McCann FE, Palfreeman AC, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther. 2010;12(3):R107.
26. The controlled trial of apremilast for rheumatoid arthritis treatment (CARAT). Available at: http://clinicaltrials.gov/ identifier: NCT01250548. Accessed December 1, 2011.
27. Study of apremilast to evaluate the safety and effectiveness for patients with rheumatoid arthritis. Available at: http://clinicaltrials.gov/ identifier: NCT01285310. Accessed December 1, 2011.
28. Concomitant use of apremilast for the treatment of active RA despite TNF-inhibition and methotrexate-CATARA. Available at: http://clinicaltrials.gov/ identifier: NCT01204138. Accessed December 1, 2011.
29. Kurzeja M, Rudnicka L, Olszewska M. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol. 2011;12(2):113–125.
30. Efficacy, safety, and tolerability of secukinumab in patients with rheumatoid arthritis taking methotrexate. Available at: http://clinicaltrials.gov/ identifier: NCT01359943. Accessed December 1, 2011.
31. Efficacy at 24 weeks and safety, tolerability and long term efficacy up to 2 years of secukinumab (AIN457) in patients with active rheumatoid arthritis and an inadequate response to anti-TNF α agents. Available at: http://clinicaltrials.gov/ identifier: NCT01377012. Accessed December 1, 2011.
32. Efficacy at 24 weeks and safety, tolerability and long term efficacy up to 1 year of secukinumab (AIN457) in patients with active rheumatoid arthritis (RA) and an inadequate response to anti-tumor necrosis factor α (anti-TNFα) agents. Available at: http://clinicaltrials.gov/ identifier: NCT01350804. Accessed December 1, 2011.
33. A biomarker study of secukinumab in rheumatoid arthritis patients. Available at: http://clinicaltrials.gov/ identifier: NCT01426789. Accessed December 1, 2011.
34. Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24):2525-2531.
35. Janssen Biotech. Press release. FDA issues complete response letter to Janssen Biotech, Inc. for Simponi supplemental biologic license application. Available at: http://www.janssenbiotech.com/assets/PressRelease07222011.pdf. Accessed December 1, 2011.
36. Orencia (abatacept) [prescribing information]. Princeton, NJ; Bristol-Myers Squibb; revised, 2011.
37. Amari W, Zeringue AL, McDonald JR, et al. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology. 2011;50(8):1431–1439.
38. FDA U.S. Food and Drug Administration. FDA Drug Safety Communication: Drug labels for the tumor necrosis factor-alpha (TNFα) blockers now include warnings about infection with Legionella and Listeria bacteria. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm. Accessed December 1, 2011.
39. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: A nationwide cohort study. Circulation. 2011:123:2226–2235.